IP Library › Granted Patent US 9,198,430
Granted Patent B2
US 9,198,430 · App. 14/129,101 · Granted Dec 1, 2015

Anti-parasitic composition comprising a macrocyclic lactone and levamisole and method of treatment of parasitic infestation

Inventors: Wayne Frederick Leech (Auckland, NZ); Fadil Al Alawi (Auckland, NZ); Karthigeyan Nanjan (Hamilton, NZ)
Assignee: BAYER NEW ZEALAND LIMITED
A01N43/90A01N57/16A61K9/0019A61K31/429A61K31/7048A61K45/06A61K47/26
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,198,430
App. No.
14/129,101
Granted
Dec 1, 2015
Kind
B2
Abstract

This invention relates to a veterinary antiparasitic solubilized composition including a macrocyclic lactone or a pharmaceutically equivalent salt thereof, and levamisole or a pharmaceutically equivalent salt thereof, characterized in that the pH of the composition is in the range of 2.0 to 5.0 and wherein the composition includes at least one surfactant and at least one antioxidant.

Claims (21)

1. A veterinary antiparasitic solubilised injectable composition comprising

a macrocyclic lactone or a pharmaceutically equivalent salt thereof, and

a levamisole salt,

wherein the pH of the composition is in the range of 2.0 to 5.0 and wherein the composition includes at least 15% w/v surfactant.

2. A composition as claimed in claim 1 wherein the effective amount of levamisole in the composition is in the range of 6.0% to 27.0% w/v.

3. A composition as claimed in claim 1 wherein the levamisole is provided in the form of levamisole hydrochloride.

4. A composition as claimed in claim 1 wherein the levamisole is provided in the form of levamisole phosphate.

5. A composition as claimed in claim 1 wherein the macrocyclic lactone is in the range of 0.2 to 1.2% w/v.

6. A composition as claimed in claim 1 further comprising a chelating agent.

7. A composition as claimed in claim 6 wherein the chelating agent is EDTA disodium.

8. A composition as claimed in claim 1 further comprising an antioxidant.

9. A composition as claimed in claim 8 wherein the antioxidant is butylated hydroxytoluene.

10. A composition as claimed in claim 1 further comprising a preservative.

11. A composition as claimed in claim 10 wherein the preservative is benzyl alcohol.

12. A composition as claimed in claim 1 further comprising a stabiliser.

13. A composition as claimed in claim 12 wherein the stabiliser is glycerine formal.

14. A composition as claimed in claim 1 wherein the concentration of surfactant in the composition is approximately 20% w/v.

15. A composition as claimed in claim 1 wherein the surfactant is Polysorbate 80.

16. A method of treating a non-human animal for parasitic infestation comprising the step of

administering to the animal the veterinary composition as claimed in claim 1 by injection.

17. A composition as claimed in claim 8 wherein the concentration of antioxidant in the composition is above 0.15% w/v.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 9, 2020
From: BAYER NEW ZEALAND LTD.
To: ELANCO NEW ZEALAND
Reel/Frame 054017/0624 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 2, 2014
From: LEECH, WAYNE FREDERICK, DR.; AL ALAWI, FADIL, DR.; NANJAN, KARTHIGEYAN, DR.
To: BAYER NEW ZEALAND LIMITED
Reel/Frame 032582/0652 →
Priority Claims (1)
NZ 593713 · Jun 23, 2011 · national
Continuity (1)
Related Publication 20140221299A1 · Aug 7, 2014